Minovia Therapeutics to Participate at Upcoming Credit Suisse Healthcare Conference on November 12th

CAMBRIDGE, Mass. & HAIFA, Israel--(BUSINESS WIRE)--Minovia Therapeutics, a clinical-stage company focused on the development of cell-based Mitochondrial Augmentation Therapy (MAT) to treat mitochondrial diseases, today announced that Co-founder and Chief Executive Officer Natalie Yivgi-Ohana, PhD will be hosting investor meetings and presenting a corporate overview at the Credit Suisse 29^th Annual Healthcare Conference on Thursday, November 12^th at 8:45 am ET.

About Minovia Therapeutics

Minovia Therapeutics is a clinical stage company and the first to use a cell therapy approach to treat people affected with mitochondrial diseases through its Mitochondrial Augmentation Therapy (MAT) platform. MAT is being developed as a robust and scalable therapeutic platform targeting the root cause of diseases generated by mitochondrial dysfunction. MAT enriches patients’ hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. Minovia’s initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments in the United States and the unmet medical need is immense. Minovia is now conducting an IND enabled phase I/II clinical trial in Pearson Syndrome, a fatal pediatric disease. Harnessing the power of mitochondria, Minovia is committed to exploring the full potential of its proprietary platform to address mitochondrial diseases ranging from orphan indications to more common diseases.

For more information, please visit http://minoviatx.com/.